dc.contributor.author | Whisenant, Jonathan | |
dc.contributor.author | Burgess, Kevin | |
dc.date.accessioned | 2021-12-02T20:29:22Z | |
dc.date.available | 2021-12-02T20:29:22Z | |
dc.date.issued | 2020-05-18 | |
dc.identifier.citation | 10.1021/acsmedchemlett.0c00233 | en_US |
dc.identifier.uri | ${sadil.baseUrl}/handle/123456789/1088 | |
dc.description | 1076-1078 p. | en_US |
dc.description.abstract | Recent crystal structure data for protein−protein interactions featuring the SARS-CoV-2 spike protein will inevitably trigger a new wave of research in this area that was not possible before. This Viewpoint outlines a few of the ways that it is already happening. | en_US |
dc.language.iso | en | en_US |
dc.publisher | ACS Medicinal Chemistry Letters | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Spike protein | en_US |
dc.subject | peptide | en_US |
dc.subject | Monoclonal antibody | en_US |
dc.title | Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps | en_US |
dc.type | Article | en_US |